Eli Lilly And Co (NYSE:LLY) Issues FY 2020 Pre-Market Earnings Guidance

Eli Lilly And Co (NYSE:LLY) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided EPS guidance of 7.20-7.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.81. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $24.01 billion.Eli Lilly And Co also updated its FY20 guidance to $7.20-$7.40 EPS.

Several equities research analysts recently issued reports on LLY shares. ValuEngine cut Eli Lilly And Co from a hold rating to a sell rating in a report on Saturday. Mizuho lifted their price target on Eli Lilly And Co from $155.00 to $164.00 and gave the stock a neutral rating in a research note on Monday, June 29th. Cowen increased their price objective on Eli Lilly And Co from $145.00 to $160.00 and gave the company an outperform rating in a research note on Wednesday, April 15th. Cantor Fitzgerald raised their price objective on Eli Lilly And Co from $156.00 to $185.00 and gave the company an overweight rating in a report on Friday, April 24th. Finally, JPMorgan Chase & Co. upped their target price on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the stock an overweight rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Eli Lilly And Co has a consensus rating of Buy and a consensus target price of $168.58.

NYSE LLY opened at $150.29 on Friday. The business’s fifty day simple moving average is $160.88 and its 200-day simple moving average is $148.62. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37. The firm has a market cap of $143.74 billion, a PE ratio of 24.40, a P/E/G ratio of 1.32 and a beta of 0.26. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $170.75.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Thursday, July 30th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.31. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The firm had revenue of $5.50 billion during the quarter, compared to analysts’ expectations of $5.77 billion. During the same period last year, the business earned $1.50 earnings per share. Eli Lilly And Co’s revenue was down 2.4% compared to the same quarter last year. Research analysts expect that Eli Lilly And Co will post 7.3 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.74 per share. The ex-dividend date of this dividend is Thursday, August 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.97%. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

In other news, major shareholder Lilly Endowment Inc sold 212,337 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.92, for a total transaction of $34,593,944.04. Following the completion of the transaction, the insider now directly owns 112,194,732 shares in the company, valued at approximately $18,278,765,737.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 17,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $162.94, for a total value of $2,769,980.00. Following the sale, the senior vice president now directly owns 39,646 shares of the company’s stock, valued at $6,459,919.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 555,236 shares of company stock worth $91,393,391. Corporate insiders own 0.09% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What are the Different Types of Leveraged Buyouts?

Earnings History and Estimates for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.